Trial Information
A Phase I Study of ZD1839 (Iressa) and Palliative Thoracic Radiotherapy in Patients With Non-small Cell Lung Cancer
Inclusion Criteria:
- Provision of written informed consent
- Patients requiring low dose palliative thoracic irradiation to a field size of less
than or equal to 150cm2
- Histologically or cytologically conformed non-small cell lung cancer
- Aged 18 or over
Exclusion Criteria:
- Previous thoracic radiotherapy
- Any condition that may pre-dispose the patient to suffer an individual drug-relaged
DLT (dose limiting toxicity) event
- Known hypersensitivity to any component of study medication
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
To characterize the safety profile of ZD 1839 in these patients
Principal Investigator
AstraZeneca Iressa Medical Sciences Director, MD
Investigator Role:
Study Director
Investigator Affiliation:
AstraZeneca
Authority:
United Kingdom: Department of Health
Study ID:
1839IL/0524
NCT ID:
NCT00255489
Start Date:
May 2004
Completion Date:
June 2006
Related Keywords:
- Non-Small-Cell Lung Cancer
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms